Long-term safety of abatacept in patients with rheumatoid arthritis

Autoimmunity Reviews

Volumn 12, Issue 12, 2013, Pages 1115-1117

  Atzeni, Fabiola ^a   Sarzi Puttini, Piercarlo ^a   Mutti, Alessandra ^a   Bugatti, Serena ^b   Cavagna, Lorenzo ^b   Caporali, Roberto ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Abatacept; Rheumatoid arthritis; Safety

Indexed keywords

ABATACEPT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; BENIGN TUMOR; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEART DISEASE; HUMAN; INFECTION; INFESTATION; INFUSION RELATED REACTION; LUNG CANCER; LUNG TUBERCULOSIS; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; NEOPLASM; OBSERVATIONAL STUDY; OPPORTUNISTIC INFECTION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; UNSPECIFIED SIDE EFFECT; VASCULITIS;

ABATACEPT; RHEUMATOID ARTHRITIS; SAFETY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOCONJUGATES; OBSERVATIONAL STUDY AS TOPIC;

EID: 84884699849     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.06.011     Document Type: Review

References (29)

1. Lee D.M., Weinblatt M.E. Rheumatoid arthritis. Lancet 2001, 358:903-911.
2. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
3. Smolen J.K., Landewé R., Breedveld F.C., Dougados M., Emery P., Gaujoux-Viala C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975.
4. Solomon G.E. T-cell agents in the treatment of rheumatoid arthritis - 2011 update. Bull NYU Hosp Jt Dis 2011, 69:230-232.
5. Buch M.H., Vital E.M., Emery P. Abatacept in the treatment of rheumatoid arthritis. Arthritis Res Ther 2008, (10 Suppl.). 1:S5.
6. von Kempis J., Dudler J., Hasler P., Kyburz D., Tyndall A., Zufferey P., et al. Use of abatacept in rheumatoid arthritis. Swiss Med Wkly 2012, 142:w13581.
7. Kremer J.M., Dougados M., Emery P., Durez P., Sibilia J., Shergy W., et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005, 52:2263-2271.
8. Westhovens R., Kremer J.M., Moreland L.W., Emery P., Russell A.S., Li T., et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol 2009, 36:736-742.
9. Kremer J.M., Genant H.K., Moreland L.W., Russell A.S., Emery P., Abud-Mendoza C., et al. Effects of abatacept in patients with methotrexate resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006, 144:865-876.
10. Kremer J.M., Russell A.S., Emery P., Abud-Mendoza C., Szechinski J., Westhovens R., et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis 2011, 70:1826-1830.
11. Schiff M., Keiserman M., Codding C., Songcharoen S., Berman A., Nayiager S., et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008, 67:1096-1103.
12. Schiff M., Keiserman M., Codding C., Songcharoen S., Berman A., Nayiager S., et al. Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study. Ann Rheum Dis 2011, 70:2003-2007.
13. Genovese M.C., Becker J.C., Schiff M., Luggen M., Sherrer Y., Kremer J., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005, 353:1114-1123.
14. Genovese M.C., Schiff M., Luggen M., Becker J.C., Aranda R., Teng J., et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 2008, 67:547-554.
15. Genovese M.C., Schiff M., Luggen M., Le Bars M., Aranda R., Elegbe A., et al. Longterm safety and efficacy of abatacept through 5years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy. J Rheumatol 2012, 39:1546-1554.
16. Schiff M., Pritchard C., Huffstutter J.E., Rodriguez-Valverde V., Durez P., Zhou X., et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis 2009, 68:1708-1714.
17. Schiff M., Pritchard C., Huffstutter J.E., et al. Safety and efficacy of abacept (ABA) in patients with rheumatoid arthritis (RA) and an inadequate response to anti-tumour necrosis factor (TNF) therapy through 2years of the ARRIVE trial. Ann Rheum Dis 2010, 69:540.
18. http://www%2Eema%2Eeuropa%2Eeu/docs/en%5FGB/document%5Flibrary/EPAR%5F%2D%2E%5FScientific%20Discussion%5F%2D%5FVariation/human/000701/WC500095025%2Epdf.
19. Weinblatt M., Combe B., Covucci A., Aranda R., Becker J.C., Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 2006, 54:2807-2816.
20. Wells A.F., Westhovens R., Reed D.M., Fanti L., Becker J.C., Covucci A., et al. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression. J Rheumatol 2011, 38:2362-2368.
21. Smitten A., Westhovens R., Hochberg M., Torbeyns A., Becker J.-C., Aranda R. Serious infections and malignancies during long-term exposure to abatacept. Ann Rheum Dis 2010, [abstracts SAT0163].
22. Hochberg M.H., Westhovens R., Aranda R., Kelly S., Khan N., Qi K., et al. Long-term safety of abatacept: integrated analysis of clinical program data of up to 7years of treatment. Arthritis Rheum 2010, [abstract 390].
23. Schiff M., Keiserman M., Codding C., Songcharoen S., Berman A., Nayiager S., et al. Incidence of anti-nuclear and anti-DNA antibody seropositivity, and immunogenicity, in patients with rheumatoid arthritis treated with abatacept or infliximab. Ann Rheum Dis 2007, [Abstract SAT003].
24. Fiocco U., Sfriso P., Oliviero F., Pagnin E., Scagliori E., Campana C., et al. Co-stimulatory modulation in rheumatoid arthritis: the role of (CTLA4-Ig) abatacept. Autoimmun Rev 2008, 8:76-82.
25. Atzeni F., Sarzi-Puttini P., Botsios C., Carletto A., Cipriani P., Favalli E.G., et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev 2012, 12:225-229.
26. Pallavicini F.B., Caporali R., Sarzi-Puttini P., Atzeni F., Bazzani C., Gorla R., et al. Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. Autoimmun Rev 2010, 9:175-180.
27. Olivieri I., Sarzi-Puttini P., Bugatti S., Atzeni F., d'Angelo S., Caporali R. Early treatment in early undifferentiated arthritis. Autoimmun Rev 2012, 11:589-592.
28. Atzeni F., Sarzi-Puttini P., Gorla R., Marchesoni A., Caporali R. Switching rheumatoid arthritis treatments: an update. Autoimmun Rev 2011, 10:397-403.
29. Atzeni F., Talotta R., Benucci M., Salaffi F., Cassinotti A., Varisco V., et al. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev 2013, 12:703-708.